Phase II, parallel-group, double-blind study with three treatment groups to evaluate the efficacy and safety of finerenone plus empagliflozin compared to finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BAYER CONSUMER CARE AG
- Phase: II
- Execution start: 08/04/2022
- End of execution: 02/12/2023
- PI: JUAN DIEGO MEDIAVILLA GARCIA